Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
59 results about "Thienopyridine Derivatives" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Tetrahydro thienopyridine derivative for treating
InactiveCN102002053AOrganic active ingredientsGroup 5/15 element organic compoundsDiseaseThienopyridine Derivatives
The invention provides a novel tetrahydro thienopyridine derivative. The dosage of one or more active compounds in the novel tetrahydro thienopyridine derivative is 0.1-20mg / kg body weight, and the preferable dosage is 0.1-5mg / kg body weight. The novel tetrahydro thienopyridine derivative can be used for producing medicines for preventing and / or treating diseases induced by thrombosis or thromboembolism.
Owner:HC SYNTHETIC PHARMA CO LTD
Process to prepare clopidogrel
InactiveUS6635763B2Increased cost-effectivenessOrganic chemistryThienopyridine DerivativesPharmacometrics
The present invention relates to a process for the preparation of thieno[3,2-c]pyridine derivatives having pharmacologically significant anti-aggregating and anti-thrombotic properties.
Owner:CADILA HEALTHCARE LTD
Thieno-pyridine derivatives as allosteric enhancers of the GABAB receptors
InactiveUS20060135552A1Valuable therapeutic propertyBiocideNervous disorderThienopyridine DerivativesMuscular spasticity
The present invention relates to compounds of formula I wherein R1, R2, R3, R4, and R5 are as defined in the specification. Compounds of the invention are active on the GABAB receptor and are useful for treating a variety of CNS disorders, including anxiety, depression, epilepsy, schizophrenia, cognitive disorders, spasticity-and skeletal muscle rigidity, spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis, cerebral palsy, neuropathic pain and craving associated with cocaine and nicotine, psychosis, panic disorder, posttraumatic stress disorders and gastrointestinal disorders.
Owner:F HOFFMANN LA ROCHE & CO AG
Process to prepare clopidogrel
The present invention relates to a process for the preparation of thieno[3,2-c]pyridine derivatives having pharmacologically significant anti-aggregating and anti-thrombotic properties.
Owner:CADILA HEALTHCARE LTD
Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
Methods and pharmaceutical compositions for treating viral infections, by administering certain thienopyridine derivative compounds in therapeutically effective amounts are disclosed. Methods of using the compounds and pharmaceutical compositions thereof are also disclosed. In particular, the treatment of viral infections such as caused by flavivirus is disclosed, i.e., including but not limited to, Dengue virus, West Nile virus, yellow fever virus, Japanese encephalitis virus, and tick-borne encephalitis virus.
Owner:SIGA TECH INC
Optically active 2-hydroxyltetrahydrothienopyridine derivative as well as preparation method and use thereof
ActiveCN103665042ASolve the problem of resistanceImprove oral bioavailabilityOrganic active ingredientsGroup 5/15 element organic compoundsArylHalogen
The invention provides an optically active 2-hydroxyltetrahydrothienopyridine derivative shown by formula I, or a pharmaceutically acceptable salt, solvate, polycrystal, enantiomer or racemization mixture thereof, wherein in the formula I, R1 is F, Cl, Br or I; m is 0 or 1; n is an integer from 1 to 6; R2 or R3 is independently hydrogen, C1-C6 alkyl or optionally substituted C1-6 alkyl; R4 or R5 is independently hydrogen, C1-C10 alkyl, C1-C10 alkenyl, C1-10 alkoxy, C1-10 aryl, halogen, acylamino, sulfmidyl, acyloxy or C(O)R', and R' is hydrogen, C1-C10 alkyl, C1-C10 alkenyl, C1-10 alkoxy, C1-10 aryl, halogen, acylamino, sulfmidyl or acyloxy. The compound has obvious platelet agglomeration resistance action, and the bioavailability of the compound is obviously higher than that of clopidogrel. The invention further provides a preparation method of the compound, a pharmaceutical composition containing the compound, and a pharmaceutical use of the compound and the pharmaceutical composition.
Owner:BEIJING PRELUDE PHARM SCI & TECH
Thienopyridine Derivatives
InactiveUS20070219234A1Enhance pharmacological effectsPromote osteogenesisBiocideOrganic chemistryThienopyridine DerivativesMedicinal chemistry
[Problem to be Solved]The present invention provides a compound promoting osteogenesis. [Solution]The present invention provides a compound having the following general formula (I) wherein R1 is H or alkyl, R2 is RaS—, RaO—, RaNH—, Ra(Rb)N— or cyclic amino, and Ra and Rb are alkyl which may be substituted, cycloalkyl which may be substituted, or the like, or a pharmacologically acceptable salt thereof.
Owner:SANKYO CO LTD
Thienopyridine derivatives and their use
InactiveUS6046189AExcellent anti-arthritic activityLow toxicityBiocideOrganic chemistryThienopyridine DerivativesArthritis
Owner:TAKEDA PHARMACEUTICALS CO LTD
Preparation method and medical application of water-soluble 2-hydroxyl tetrahydrothienopyridine derivatives
The invention relates to the field of pharmacy and specifically relates to water-soluble 2-hydroxyl tetrahydrothienopyridine derivatives as well as a preparation method of the derivatives and application of the derivatives in pharmacy, and specifically relates to application of the water-soluble 2-hydroxyl tetrahydrothienopyridine derivatives in preparation of drugs for preventing or treating thrombus and embolism related diseases, and in particular to application of the water-soluble 2-hydroxyl tetrahydrothienopyridine derivatives in prevention and treatment of acute ST segment elevation type myocardial infarction as injections.
Owner:JIANGSU VCARE PHARMATECH
Thienopyridine derivatives, and preparation methods and medical use thereof
ActiveCN103694250AMetabolic avoidanceSolve the problem of resistanceOrganic chemistryBlood disorderClopidogrel resistanceLiver and kidney
The invention belongs to the field of pharmaceutical chemistry technology, and particularly discloses thienopyridine derivatives, and preparation methods and a medical use thereof. Through structural modification of clopidogrel and prasugrel, a series of new thienopyridine derivative compounds are synthesized and mainly include derivatives esterified with ligustrazine formic acid and shikimic acid; the compounds go into a body, then are rapidly metabolized into effective metabolites and ligustrazine formic acid or shikimic acid, successfully keep away from metabolism of CYP2C19 enzyme, can be directly metabolized into active compounds to play a pharmacological function, thereby solving the clopidogrel resistance problem, effectively improving the compound antithrombotic activity, and also having no significant effect on hemorrhage risk; and the compounds have relatively ideal protective function on liver and kidney, and also have potential therapeutic significance for other cardiovascular diseases.
Owner:WUHAN QR PHARMA CO LTD
Thienopyridine derivatives, their production and use
InactiveUS6653476B2Low toxicityGood anti-inflammatory activityBiocideOrganic chemistryThienopyridine DerivativesTerthiophene
The present invention provides thienopyridine derivatives, which are useful as anti-inflammatory drugs, particularly as remedies for arthritis; processes for producing them, and pharmaceutical compositions containing them. The thienopyridine derivatives are represented by the formula (I):wherein G is a halogen atom, hydroxyl group, an optionally substituted amino group, etc.; alk is an optionally substituted lower alkylene group; X is O, S, -(CH2)q-, etc.; R is an optionally substituted amino group, etc.; ring B is an optionally substituted Y-containing 5- to 8-membered ring whose ring constituent atoms contain no nitrogen atom; Y is O, S, a group of(wherein Ra, Rb and Rc are the same or different and, each is H, a halogen atom, an optionally substituted hydrocarbon group, etc.), etc.; and ring A may be substituted.
Owner:TAKEDA PHARMA CO LTD
Metabolin marker of 2-hydroxyl radical tetrahydro-thiophene pyridine derivative with optical activity as well as preparation and application thereof
The invention relates to the field of medicines, in particular to a novel metabolin marker and application of the metabolin marker to develop or prepare a medicine containing the 2-hydroxyl radical tetrahydro-thiophene pyridine derivative with the optical activity. The medicines can be used for preventing or treating diseases caused by thrombus. The invention further provides a preparation method of the novel metabolin marker.
Owner:JIANGSU VCARE PHARMATECH
Thienopyridine derivatives and use thereof as hsp90 modulators
The invention relates to novel thienopyridine derivatives of formula (I), where R<1>, R<2>, R<3> and Y have the meanings given in claim 1, which are HSP90 inhibitors and can be used for the production of a medicament for the treatment of diseases in which the inhibition, regulation and / or modulation of HSP90 play a role.
Owner:MERCK PATENT GMBH
Thienopyridine derivatives, preparation method and application thereof
InactiveCN101830911AInhibits platelet aggregationPrevent or treat coronary syndromeOrganic active ingredientsOrganic chemistryThienopyridine DerivativesHalogen
The invention belongs to the technical field of drugs resisting platelet aggregation, in particular to thienopyridine derivatives with the structure of a formula I and salts thereof, wherein n is equal to 0 and 1; R1 is C1-C4 alkyl; R2 and R3 are simultaneously or respectively hydrogen, C1-C4 alkyl, C1-C4 alkoxy, halogen and halogenated methyl; and R4 is C1-C4 alkyl. The invention also relates to a preparation method of the compounds, and discloses a drug composition with the compounds or salts thereof as active effective components, and application of the compounds in preparing the drugs for resisting the platelet aggregation.
Owner:TIANJIN INSTITUTE OF PHARMA RESEARCH
Thienopyridine derivative for the treatment of hepatitis c infections
ActiveUS20170014394A1Peptide/protein ingredientsHeterocyclic compound active ingredientsThienopyridine DerivativesPyridine
Owner:CIPLA UK LTD
Deuterated thienopyridine derivative, and preparation method and application thereof
InactiveCN107698620AGroup 5/15 element organic compoundsOrganic chemistry methodsDiseaseThienopyridine Derivatives
The invention relates to a deuterated thienopyridine derivative, and a preparation method and an application thereof. The deuterated thienopyridine derivative provided by the invention has a structureas shown in a formula (I) which is described in the specification. The invention also comprises an application of the deuterated thienopyridine derivative as a drug used for treatment and preventionof cardiovascular and cerebrovascular diseases.
Owner:JIANGSU TASLY DIYI PHARMA CO LTD
Preparation method of 2-formamido thienopyridine derivatives and medical uses
InactiveCN101684123AImprove anti-tumor effectOrganic active ingredientsOrganic chemistryThienopyridine DerivativesActive component
The invention discloses preparation method of 2-formamido thienopyridine derivatives and uses in preparing antineoplastic medicine compositions, The experiment results show that the 2-formamido thienopyridine derivatives has antitumor action, which can be used as main active components to prepare new antineoplastic medicine and provide new selection for treatment of tumour.
Owner:SICHUAN UNIV
Thienopyridines
The invention relates to novel thienopyridine derivatives of formula (I), wherein R1, R2, R3, R4 and Y have the meaning cited in claim 1, are HSP90-inhibitors and can be used for producing a medicament for treating illnesses, wherein the inhibition, regulation and / or modulation of HSP90 plays a roll.
Owner:MERCK PATENT GMBH
Tetrahydrothienopyridine deuterated derivative as well as preparation method and pharmaceutical application thereof
ActiveCN114736215AImprove conversion rateSolve the problem of resistanceOrganic active ingredientsOrganic chemistry methodsDiseaseThienopyridine Derivatives
The invention discloses a tetrahydrothienopyridine deuterated derivative as well as a preparation method and pharmaceutical application thereof. The derivative can be used for preparing medicines for preventing or treating thrombus-related diseases. The thienopyridine derivative can balance and optimize the safety and effectiveness of a medicine, the thienopyridine derivative is prevented from being hydrolyzed too fast in the gastrointestinal tract, and a better treatment effect is achieved on the premise that the bleeding risk of a patient is not increased.
Owner:ZHONGRONG KAITE BEIJING BIOTECH CO LTD
Polysubstituted thieno[2,3-b]pyridine derivatives, and preparation method and application thereof
ActiveCN110627809AGood selective diuretic effectIncrease urine outputOrganic chemistryBlood disorderErythrocyte membraneCytotoxicity
The invention discloses polysubstituted thieno[2,3-b]pyridine derivatives, and a preparation method and an application thereof. The structural formula of the derivatives are represented by formula I shown in the description. A compound for inhibiting a urea transporter is screened by using an erythrocyte model. Experimental results show that the compounds (represented by formula I-1) can inhibit the permeation of a urea transporter UT-B mediated erythrocyte membrane to urea, and the effect of the compounds has a dose-dependent relationship; the compounds represented by the formula I-1 have nocytotoxic effect on MDCK cells within an effective dose range, so the effect of the compounds represented by the formula I-1 on inhibiting cell permeation urea is irrelevant to the cytotoxicity of thecompounds; the inhibition effect of the compounds represented by the formula I-1 on the urea transporter UT-B is gradually enhanced; the inhibiting effect of the compounds represented by the formulaI-1 on the UT-B is reversible; and in-vivo test results show that the compounds represented by the formula I-1 can significantly increase the urination volume of rats, reduce the concentration of ureain rat urine and reduce the osmotic pressure, so that the compounds represented by the formula I-1 generate a urea selective diuresis effect in vivo.
![Polysubstituted thieno[2,3-b]pyridine derivatives, and preparation method and application thereof](https://images-eureka.patsnap.com/patent_img/350d3015-5b05-4d00-a376-c9e55766159c/HDA0001704146070000011.png "Polysubstituted thieno[2,3-b]pyridine derivatives, and preparation method and application thereof")
![Polysubstituted thieno[2,3-b]pyridine derivatives, and preparation method and application thereof](https://images-eureka.patsnap.com/patent_img/350d3015-5b05-4d00-a376-c9e55766159c/HDA0001704146070000012.png "Polysubstituted thieno[2,3-b]pyridine derivatives, and preparation method and application thereof")
![Polysubstituted thieno[2,3-b]pyridine derivatives, and preparation method and application thereof](https://images-eureka.patsnap.com/patent_img/350d3015-5b05-4d00-a376-c9e55766159c/HDA0001704146070000013.png "Polysubstituted thieno[2,3-b]pyridine derivatives, and preparation method and application thereof")
Owner:PEKING UNIV
Thienopyrimidine and thienopyridine derivatives substituted with cyclic amino group
An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc. A thienopyrimidine or thienopyridine derivative substituted with a cyclic amino group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.
Owner:TAISHO PHARMACEUTICAL CO LTD
Thienopyridine derivative, and preparation method and application thereof
InactiveCN102030759AHigh reaction yieldHigh yieldOrganic active ingredientsOrganic chemistryThienopyridine DerivativesApoptosis
The invention discloses a thienopyridine derivative with a novel structure, a preparation method thereof and application thereof, and belongs to the field of medicaments. A pharmacological test proves that the thienopyridine derivative shown as a formula 4 has remarkable proliferation inhibition effect on human hepatoma cells HepG2 and the proliferation inhibition effect is achieved by inducing apoptosis; and a new anti-tumor medicament prepared from a 3-amino-thieno[2,3-b]pyridine-2-formamide derivative serving as a main active ingredient is a new choice for the treatment of tumors.
Owner:SICHUAN UNIV
Bi-thienopyridine type derivative and preparation method thereof
InactiveCN105017279ARaw materials are cheap and easy to getEasy to operateOrganic chemistryLuminescent compositionsThienopyridine DerivativesLight emitting device
The invention discloses a bi-thienopyridine type derivative and a preparation method thereof. The bi-thienopyridine derivative disclosed by the invention adopts a rigid near plane structure, a skeleton structure is the combination of thiophthene and pyridine, a conjugation system is larger, and the double-thienopyridine derivative belongs to the technical field of synthesis. The general formula of a preparation reaction is shown as follows. The coordination compound uses 3, 4-diamino thieno [2, 3-b] thiophene -2, 5- denitrile as a raw material, under the induction of a catalyst, the raw material and ketone or aldehyde generate a Friedlander reaction, and a series of bi-thienopyridine derivatives are synthesized in a one-pot method. The operation process is simple, the atom economy is high, the reaction conditions are mild, and the yield is high. The material of the derivative can be used as a luminescent material, and can be used as the material of a luminous layer in a light emitting device. The synthetic method is one of the manners of magnetic stirring, hydrothermal reactions, microwaves, solid phase synthesis and the like. Through the adoption of the preparation method disclosed by the invention, different substrates can be used for synthesizing various bi-thienopyridine type derivatives which are not reported in literatures.
Owner:BEIJING INSTITUTE OF TECHNOLOGYGY
Thienopyridine derivatives , their production and use
InactiveUS20030130517A1Superior prophylacticSuperior therapeutic efficacyOrganic active ingredientsOrganic chemistryThienopyridine DerivativesTerthiophene
The present invention provides thienopyridine derivatives, which are useful as anti-inflammatory drugs, particularly as remedies for arthritis; processes for producing them, and pharmaceutical compositions containing them. The thienopyridine derivatives are represented by the formula (I): wherein G is a halogen atom, hydroxyl group, an optionally substituted amino group, etc.; alk is an optionally substituted lower alkylene group; X is O, S, -(CH2)q-, etc.; R is an optionally substituted amino group, etc.; ring B is an optionally substituted Y-containing 5- to 8-membered ring whose ring constituent atoms contain no nitrogen atom; Y is O, S, a group of (wherein Ra, Rb and Rc are the same or different and, each is H, a halogen atom, an optionally substituted hydrocarbon group, etc.), etc.; and ring A may be substituted.
Owner:TAKEDA PHARMA CO LTD
Thienopyridine derivative
InactiveCN1968954APromotes bone formationInhibition of bone resorptionOrganic chemistryAntipyreticThienopyridine DerivativesPerylene derivatives
The invention provides osteogenesis-promoting compounds, namely, compounds represented by the general formula (I) and pharmacologically acceptable salts thereof: wherein R<1> is H or alkyl; R<2> is RS-, RO-, RNH-, R(R)N-, or cyclic amino; and R and R are each optionally substituted alkyl, optionally substituted cycloalkyl, or the like.
Owner:SANKYO CO LTD
Thienopyridine derivatives and their use
InactiveUS6403606B1Low toxicityHigh activityBiocideOrganic chemistryThienopyridine DerivativesArthritis
There is disclosed a compound of the formula (A):wherein W is C-G or C-G' (G is optionally esterified carboxyl; and G' is halogen); X is oxygen, optionally oxidized sulfur or -(CH2)q-, (q is 0 to 5); R is optionally substituted amino or heterocyclic group; the ring B is optionally substituted nitrogen-containing 5- to 7-membered ring; L is hydrogen, optionally substituted hydrocarbon residue, optionally substituted acyl, optionally substituted carbamoyl, optionally substituted thiocarbamoyl or optionally substituted sulfonyl provided that, when W is C-G, L is hydrogen, optionally substituted acyl, optionally substituted carbamoyl, optionally substituted alkoxycarbonyl, optionally substituted thiocarbamoyl or optionally substituted sulfonyl; n is 0 or 1; the ring A may have a substituent. A process for producing the compound (A) and a pharmaceutical composition containing the compound (A) are also disclosed. The pharmaceutical composition is useful for an anti-inflammatory drug, particularly, a drug for preventing or treating arthritis, a drug for inhibiting bone resorption, immunosuppressant or the like.
Owner:TAKEDA PHARMA CO LTD
Thienopyridine derivatives for the treatment and prevention of dengue virus infections
Owner:SIGA TECH INC
Thienopyridine derivative for the treatment of hepatitis C infections
ActiveUS9937160B2Peptide/protein ingredientsHeterocyclic compound active ingredientsThienopyridine DerivativesPrasugrel
Owner:CIPLA UK LTD
Synthetic method of pyrazolo[3,4-b]thieno[2,3-e]pyridine derivative
The invention relates to synthesis of a pyrazolo[3,4-b]thieno[2,3-e]pyridine derivative, in particular to synthesis of pyrazolo[3,4-b]thieno[2,3-e]pyridine. The pyrazolo[3,4-b]thieno[2,3-e]pyridine derivative is generated by taking aromatic aldehyde, 1-phenyl-3-methyl-5-aminopyrazole and 3-oxosulfolane as raw materials in one step under a solvent-free and catalyst-free condition with a three-component one-pot process. According to the method, a synthesis process has a simple and convenient route, conditions are mild, and the total yield is over 78 percent.
![Synthetic method of pyrazolo[3,4-b]thieno[2,3-e]pyridine derivative](https://images-eureka.patsnap.com/patent_img/d3750581-e0ef-4540-a58a-1a7705a08295/HSA00000717202300011.PNG "Synthetic method of pyrazolo[3,4-b]thieno[2,3-e]pyridine derivative")
![Synthetic method of pyrazolo[3,4-b]thieno[2,3-e]pyridine derivative](https://images-eureka.patsnap.com/patent_img/d3750581-e0ef-4540-a58a-1a7705a08295/BSA00000717202200021.PNG "Synthetic method of pyrazolo[3,4-b]thieno[2,3-e]pyridine derivative")
Owner:XUZHOU NORMAL UNIVERSITY
Thienopyridine derivative, method for producing same and organic semiconductor device using same
Disclosed is a novel thienopyridine derivative shown by general formula (1) that is useful as an organic semiconductor device and specifically as an organic thin film transistor. Also disclosed is a method for producing the same. [In the formula, R<1> is a hydrogen atom, optionally substituted alkyl group, optionally substituted alkenyl group, optionally substituted alkynyl group, optionally substituted alkoxy group, optionally substituted aryl group, optionally substituted heteroaromatic ring group, optionally substituted alkylthio group, optionally substituted arylthio group, optionally substituted ester group or a substituent shown by -SO2R<2> (wherein R<2> is an optionally substituted C1-20 hydrocarbon group), and W is at least one substituent selected from a group comprising optionally substituted aryl groups and optionally substituted heteroaromatic ring groups.]
Owner:HIROSHIMA UNIVERSITY +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com